2.77

6.95% 0.18

Solid Biosciences Inc (SLDB)

Überblick Nachrichten Preisverlauf Optionskette Financials Warum fällt SLDB? Forum Prognose Aktiensplit

Schlusskurs vom Vortag:

$2.59

Offen:

$2.89

24-Stunden-Volumen:

4.05M

Relative Volume:

1.47

Marktkapitalisierung:

$214.68M

Einnahmen:

$14.79M

Nettoeinkommen (Verlust:

$-102.44M

KGV:

-0.9112

EPS:

-3.04

Netto-Cashflow:

$-91.73M

1W Leistung:

+0.36%

1M Leistung:

+9.92%

6M Leistung:

-42.89%

1J Leistung:

-70.22%

1-Tages-Spanne:

$2.68

$2.93

1-Wochen-Bereich:

$2.41

$3.005

52-Wochen-Spanne:

$2.41

$10.37

Solid Biosciences Inc Stock (SLDB) Company Profile

Firmenname

Solid Biosciences Inc

Sektor

Healthcare (1170)

Branche

Biotechnology (671)

Telefon

617-337-4680

Adresse

500 RUTHERFORD AVENUE, CHARLESTOWN, MA

Mitarbeiter

100

Twitter

@SolidBioDMD

Nächster Verdiensttermin

2024-11-06

Neueste SEC-Einreichungen

SLDB's Discussions on Twitter

Vergleichen Sie SLDB mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
SLDB Solid Biosciences Inc	2.77	213.90M	14.79M	-102.44M	-91.73M	-3.04
ONC Beigene Ltd Adr	228.38	25.07B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	438.65	109.14B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.27	36.39M	0	0	0	0.00
REGN Regeneron Pharmaceuticals Inc	594.32	56.98B	14.09B	4.50B	2.96B	39.28
VRNA Verona Pharma Plc Adr	71.31	5.39B	0	-153.72M	-103.81M	-2.00

Solid Biosciences Inc Stock (SLDB) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2025-01-08	Eingeleitet	Truist	Buy
2024-12-13	Eingeleitet	Wedbush	Outperform
2024-12-10	Eingeleitet	JMP Securities	Mkt Outperform
2024-07-15	Hochstufung	JP Morgan	Neutral → Overweight
2024-06-24	Hochstufung	Leerink Partners	Market Perform → Outperform
2024-05-31	Fortgesetzt	Piper Sandler	Overweight
2024-03-28	Eingeleitet	William Blair	Outperform
2024-03-15	Eingeleitet	Citigroup	Buy
2024-03-14	Hochstufung	Piper Sandler	Neutral → Overweight
2023-12-08	Eingeleitet	H.C. Wainwright	Buy
2021-07-12	Eingeleitet	Piper Sandler	Neutral
2021-05-27	Eingeleitet	Jefferies	Buy
2021-03-16	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2021-03-09	Eingeleitet	Barclays	Overweight
2021-01-08	Hochstufung	Credit Suisse	Underperform → Neutral
2020-07-28	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2020-05-07	Herabstufung	Evercore ISI	Outperform → In-line
2019-10-11	Eingeleitet	Evercore ISI	Outperform
2019-08-29	Herabstufung	Citigroup	Neutral → Sell
2019-08-19	Hochstufung	SVB Leerink	Mkt Perform → Outperform
2019-08-16	Hochstufung	Chardan Capital Markets	Neutral → Buy
2019-05-14	Herabstufung	Credit Suisse	Neutral → Underperform
2019-05-14	Herabstufung	Goldman	Neutral → Sell
2019-02-08	Hochstufung	Citigroup	Sell → Neutral
2019-02-08	Herabstufung	SVB Leerink	Outperform → Mkt Perform
2018-11-06	Eingeleitet	Citigroup	Sell
2018-09-06	Eingeleitet	Credit Suisse	Neutral

Alle ansehen

Solid Biosciences Inc Aktie (SLDB) Neueste Nachrichten

May 16, 2025

SLDB: Piper Sandler Lowers Price Target for Solid Biosciences | SLDB Stock News - GuruFocus

May 16, 2025

Truist maintains buy on Solid Biosciences stock, price target at $16 - Investing.com

May 16, 2025

Solid Biosciences (SLDB) Maintains Overweight Rating Amid Price Target Adjustment | SLDB Stock News - GuruFocus

May 16, 2025

Solid Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView

May 16, 2025

Solid Biosciences (SLDB) Target Price Revised Amid Share Count Changes | SLDB Stock News - GuruFocus

May 16, 2025

Wedbush Cuts Price Target on Solid Biosciences to $17 From $18, Keeps Outperform Rating - marketscreener.com

May 16, 2025

Solid Biosciences (SLDB) Sees Price Target Cut by Piper Sandler Amid Trial Updates | SLDB Stock News - GuruFocus

May 16, 2025

Solid Biosciences: Promising Gene Therapy Advancements and Strategic Initiatives Drive Buy Rating - TipRanks

May 16, 2025

Barclays Adjusts Price Target for Solid Biosciences (SLDB) Amid Progress | SLDB Stock News - GuruFocus

May 16, 2025

May 15, 2025

Solid Biosciences Files $400 Million Mixed Shelf - marketscreener.com

May 15, 2025

Solid Biosciences Files Prospectus for $85 Million Offering - TipRanks

May 15, 2025

SLDB Shows Promise with Early Results in Duchenne Muscular Dystrophy Trial | SLDB Stock News - GuruFocus

May 15, 2025

Solid Biosciences (SLDB) Files for $400 Million Mixed Securities Shelf | SLDB Stock News - GuruFocus

May 15, 2025

Solid Biosciences Inc Files For Mixed Shelf Of Up To $400 Million - marketscreener.com

May 15, 2025

Form 424B5 Solid Biosciences Inc. - StreetInsider

May 15, 2025

Solid Biosciences Reports First Quarter 2025 Financial Results a - GuruFocus

May 15, 2025

Solid Biosciences Reports First Quarter 2025 Financial Results and Provides Business Updates - GlobeNewswire

May 15, 2025

May 13, 2025

Partner With Us - Solid Biosciences

May 13, 2025

May 01, 2025

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

May 01, 2025

Solid Biosciences Expands Team: 81,000 RSUs Awarded to 7 Strategic New Hires - Stock Titan

May 01, 2025

Apr 30, 2025

Solid Biosciences to Participate at The Citizens Life Sciences Conference - The Manila Times

Apr 30, 2025

Exclusive: Solid Biosciences CEO Ready to Reveal Latest Company Vision at Major Life Sciences Event - Stock Titan

Apr 30, 2025

Apr 29, 2025

Solid Biosciences to Present at the American Society of Gene and Cell Therapy's 28th Annual Meeting - The Manila Times

Apr 29, 2025

Solid Biosciences to Present Phase 1/2 Trial Data for SGT-003 Gene Therapy at ASGCT 2025 Annual Meeting - Nasdaq

Apr 29, 2025

Solid Biosciences to Present at the American Society of Gene and Cell Therapy’s 28th Annual Meeting - GlobeNewswire

Apr 29, 2025

New Duchenne Treatment Breakthrough: Solid Bio Unveils Critical Gene Therapy Trial Results at Major Conference - Stock Titan

Apr 29, 2025

Apr 28, 2025

Montai Therapeutics Appoints Allison Bogosian, JD, as Chief People and Administrative Officer - Business Wire

Apr 28, 2025

Apr 21, 2025

Piper Sandler Remains a Buy on Solid Biosciences (SLDB) - The Globe and Mail

Apr 21, 2025

Apr 19, 2025

Certain Restricted Stock Units of Solid Biosciences Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com

Apr 19, 2025

Certain Common Stock of Solid Biosciences Inc. are subject to a Lock-Up Agreement Ending on 20-APR-2025. - marketscreener.com

Apr 19, 2025

Apr 16, 2025

Solid Biosciences stock hits 52-week low at $2.47 By Investing.com - Investing.com South Africa

Apr 16, 2025

Solid Biosciences stock hits 52-week low at $2.47 - Investing.com Australia

Apr 16, 2025

Apr 13, 2025

Can Solid Biosciences Challenge Sarepta in the DMD Market? - MSN

Apr 13, 2025

Apr 08, 2025

Solid Biosciences: A Strong Buy As An Emerging Biotech In The Gene Therapy Space - Seeking Alpha

Apr 08, 2025

Apr 07, 2025

Solid Biosciences stock hits 52-week low at $2.88 - Investing.com Australia

Apr 07, 2025

Solid Biosciences stock hits 52-week low at $2.88 By Investing.com - Investing.com South Africa

Apr 07, 2025

Solid Biosciences to Participate at Upcoming Investor Conferences - GlobeNewswire

Apr 07, 2025

Exclusive Access: Solid Biosciences Leadership Team Headlines Two Major Healthcare Conferences - Stock Titan

Apr 07, 2025

Apr 01, 2025

Solid Biosciences reports inducement grants under Nasdaq listing rule - TipRanks

Apr 01, 2025

Solid Biosciences Expands Team with 43,374 RSU Grants in Strategic Hiring Move - Stock Titan

Apr 01, 2025

Mar 20, 2025

Sarepta safety update on Elevidys boosts Regenxbio, hurts Solid Bio - MSN

Mar 20, 2025

Truist Financial Keeps Their Buy Rating on Solid Biosciences (SLDB) - The Globe and Mail

Mar 20, 2025

Mar 19, 2025

Solid Biosciences Inc.'s (NASDAQ:SLDB) market cap dropped US$53m last week; Private equity firms bore the brunt - simplywall.st

Mar 19, 2025

Mar 18, 2025

Regenxbio stock up, Solid Bio down post Sarepta update (RGNX) - Seeking Alpha

Mar 18, 2025

Mar 14, 2025